Fate Therapeutics Inc (FATE)
Healthcare
Biotechnology
2.50 $
-2.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Fate Therapeutics Inc (FATE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.4% of the shares are freely tradable; institutional investors hold 72.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
72.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
87.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.5%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
117Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Redmile Group, LLC | 11.04 | 12,872,946 | +0.0 | 03/31/2026 |
| BlackRock Inc | 8.64 | 10,068,614 | -1.1 | 03/31/2026 |
| Vanguard Group Inc | 7.70 | 8,971,347 | +2.0 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.60 | 4,192,063 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 3.55 | 4,134,585 | +0.0 | 03/31/2026 |
| Acadian Asset Management LLC | 3.53 | 4,120,200 | +44,203.2 | 03/31/2026 |
| Two Sigma Investments LLC | 2.97 | 3,466,786 | +99.9 | 03/31/2026 |
| Johnson & Johnson | 2.90 | 3,379,064 | +0.0 | 03/31/2026 |
| AQR Capital Management LLC | 2.58 | 3,001,521 | +158.3 | 03/31/2026 |
| Renaissance Technologies Corp | 2.55 | 2,974,683 | +26.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.